Dovitinib (TKI-258, CHIR-258): Multitargeted RTK Inhibition for Cancer Research

Executive Summary: Dovitinib (TKI-258, CHIR-258) is a potent multitargeted receptor tyrosine kinase (RTK) inhibitor with nanomolar affinity for FGFR, VEGFR, c-Kit, and PDGFR, blocking phosphorylation and downstream ERK/STAT5 signaling (APExBIO). It induces apoptosis and cell cycle arrest in multiple myeloma, hepatocellular carcinoma, and Waldenström macroglobulinemia models (Adams et al., 2025). Dovitinib enhances cancer cell sensitivity to apoptosis-inducing agents via SHP-1-dependent STAT3 inhibition. In vivo, it shows robust tumor suppression at up to 60 mg/kg without notable toxicity. Molecular properties and solubility data facilitate integration into diverse preclinical workflows (APExBIO).

Biological Rationale

Receptor tyrosine kinases (RTKs) are essential regulators of cell proliferation, survival, and angiogenesis. Dysregulation of RTK signaling, including the fibroblast growth factor receptors (FGFR1/3), vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptors (PDGFRα/β), c-Kit, and FLT3, is implicated in oncogenesis, tumor progression, and metastasis (Adams et al., 2025). Tumor microenvironment modulation and pre-metastatic niche (PMN) formation involve RTK-driven recruitment of myeloid progenitor cells (MPCs), which express markers such as CD14, CD34, and VEGFR1/2. Targeting these pathways is central to suppressing tumor growth and metastasis. Dovitinib, as a multitargeted RTK inhibitor, addresses this complexity by simultaneously inhibiting several oncogenic drivers. This expands its utility beyond single-pathway inhibition, aligning with modern oncology research priorities (see prior review — this article adds mechanistic depth and recent validation data).

Mechanism of Action of Dovitinib (TKI-258, CHIR-258)

Dovitinib competitively inhibits the ATP-binding sites of multiple RTKs, including FGFR1/3, VEGFR1-3, PDGFRα/β, c-Kit, and FLT3. Reported IC₅₀ values for these targets are in the 1–10 nM range under standard kinase assay conditions (25°C, pH 7.4; APExBIO). By blocking RTK phosphorylation, Dovitinib suppresses downstream ERK and STAT5 signaling, halting cell cycle progression at G1 or G2 and inducing apoptosis. In myeloma and carcinoma cells, it also enhances sensitivity to TRAIL and tigatuzumab via SHP-1-mediated inhibition of STAT3. These multifaceted effects disrupt both tumor cell-intrinsic and microenvironmental survival signals. Dovitinib is highly soluble in DMSO (≥36.35 mg/mL), insoluble in water or ethanol, and is supplied as (3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one, molecular weight 392.43 g/mol.

Evidence & Benchmarks

• Dovitinib inhibits phosphorylation of FGFR1, VEGFR2, and PDGFRβ with IC₅₀ values of 1–10 nM in recombinant kinase assays (APExBIO, product page).
• In multiple myeloma cell lines, Dovitinib induces apoptosis and cell cycle arrest within 24–48 hours of exposure at concentrations ≥50 nM (Adams et al., 2025, DOI).
• Combination of Dovitinib with TRAIL or tigatuzumab leads to synergistic apoptosis via SHP-1-dependent STAT3 inhibition in preclinical models (Adams et al., 2025).
• In vivo, Dovitinib at up to 60 mg/kg significantly suppresses tumor growth in murine models of hepatocellular carcinoma without causing notable toxicity (Adams et al., 2025).
• Dovitinib’s inhibition of RTK-driven signaling impairs recruitment and transformation of myeloid progenitor cells, potentially disrupting pre-metastatic niche formation (Adams et al., 2025).
• Solubility and handling: Stable in DMSO at ≥36.35 mg/mL, store at -20°C, short-term use recommended; insoluble in water/ethanol (APExBIO).

Applications, Limits & Misconceptions

Dovitinib is widely utilized in preclinical models of multiple myeloma, hepatocellular carcinoma, and Waldenström macroglobulinemia to dissect RTK signaling and evaluate combinatorial regimens (see workflow guide — this article clarifies solubility and mechanistic data). It enables functional screening for apoptosis induction and cell cycle modulation, and supports studies on tumor-microenvironment interactions, such as MPC recruitment and PMN formation.

Common Pitfalls or Misconceptions

• Dovitinib is not selective for a single RTK; off-target effects may confound pathway-specific studies if not controlled (use appropriate controls).
• Insolubility in water or ethanol can cause precipitation and loss of activity if not formulated in DMSO as recommended (≥36.35 mg/mL).
• Short-term solution stability limits its use in prolonged in vitro or in vivo experiments—prepare fresh aliquots for each run.
• Dovitinib’s preclinical efficacy does not equate to clinical effectiveness; translation to human therapy requires further validation.
• It does not directly target non-RTK-mediated signaling; activity is limited to RTK-driven oncogenic pathways.

Workflow Integration & Parameters

For optimal use, Dovitinib (TKI-258, CHIR-258) should be dissolved in DMSO to a working concentration, filtered, and aliquoted for storage at -20°C. In vitro, effective concentrations range from 10–500 nM, with exposure times of 24–72 hours, depending on cell line and endpoint. For in vivo studies, dosing up to 60 mg/kg/day (oral or IP) is supported by murine tolerability data. Implement appropriate vehicle and pathway controls to isolate specific RTK inhibition effects. Refer to this data-driven workflow article—the present review updates with solubility handling and mechanistic synergy.

Researchers should consult the official APExBIO Dovitinib product page for detailed specifications (SKU: A2168), regulatory status, and latest safety recommendations.

Conclusion & Outlook

Dovitinib (TKI-258, CHIR-258) is a validated tool compound for multitargeted RTK inhibition in cancer biology research. Its robust nanomolar activity against FGFR, VEGFR, PDGFR, c-Kit, and FLT3 has enabled new insights into apoptosis, cell cycle regulation, and tumor-microenvironment crosstalk. While its broad spectrum and solubility profile require careful workflow design, Dovitinib remains central to studies of RTK-driven malignancies, PMN formation, and combinatorial anti-cancer strategies. For further mechanistic and translational discussions, see the recent review—this article provides updated, granular benchmarks and practical considerations.